Roche, ImmunoGen Win Approval for Breast-Cancer Therapy

Roche Holding AG and ImmunoGen Inc. won U.S. approval for a breast cancer therapy that’s designed to narrowly target the disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.